682812-14-2

Upstream product

• 625-35-4 trans-chrotonyl chloride 
• 4248-19-5 tert-butyl carbazate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1300695-70-8 1,1-dimethylethyl (3-{[4-(4-methyl-1H-imidazol-1-yl)phenyl]amino}butanoyl)carbamate 
• 682812-19-7 tert-butyl 3-anilinobutanoylcarbamate 

Relevant academic research and scientific papers

TETRAHYDROQUINOLINE-BASED BROMODOMAIN INHIBITORS

In one aspect, compounds and compositions that modulate a bromodomain and methods of making and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with inhibition of a bromodomain such as, for example, cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Tetrahydroquinoline Derivatives And Their Pharmaceutical Use

Tetrahydroquinoline compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE

Tetrahydroquinoline compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS

Tetrahydroquinoline compounds of formula (I) or a salt thereof, pharmaceutical compositions containing such compounds and their use in therapy, in particular in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

Method of hydroaminating N-alkenoylcarbamates with primary aromatic amines

The invention provides methods for hydroaminating N-alkenoyl carbamates with aromatic amines.

Asymmetric synthesis of β-amino acid and amide derivatives by catalytic conjugate addition of aromatic amines to N-alkenoylcarbamates

We report a highly active palladium catalyst for the enantioselective conjugate addition of primary aromatic amines to N-alkenoylcarbamates, furnishing β-amino N-Boc-amides in extremely high yields (>99%) and unprecedented optical purity (>99% ee) with just 2 mol % catalyst loading. Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2004.